Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Retained Earnings (2024 - 2026)

Maze Therapeutics' Retained Earnings history spans 3 years, with the latest figure at -$513.8 million for Q1 2026.

  • On a quarterly basis, Retained Earnings fell 31.34% to -$513.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$513.8 million, a 31.34% decrease, with the full-year FY2025 number at -$489.5 million, down 36.58% from a year prior.
  • Retained Earnings hit -$513.8 million in Q1 2026 for Maze Therapeutics, down from -$489.5 million in the prior quarter.
  • Over the last five years, Retained Earnings for MAZE hit a ceiling of -$358.4 million in Q4 2024 and a floor of -$513.8 million in Q1 2026.
  • Historically, Retained Earnings has averaged -$438.8 million across 3 years, with a median of -$439.9 million in 2025.
  • Biggest five-year swings in Retained Earnings: crashed 36.58% in 2025 and later plummeted 31.34% in 2026.
  • Tracing MAZE's Retained Earnings over 3 years: stood at -$358.4 million in 2024, then tumbled by 36.58% to -$489.5 million in 2025, then fell by 4.95% to -$513.8 million in 2026.
  • Business Quant data shows Retained Earnings for MAZE at -$513.8 million in Q1 2026, -$489.5 million in Q4 2025, and -$455.0 million in Q3 2025.